NCT02367651View on ClinicalTrials.gov

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Sarcoma, Soft Tissue
Interventions
DRUG

Pazopanib 800 mg

Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib

DRUG

Placebo

Tablets matching the 200 mg and 400 mg pazopanib tablets

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02367651 - Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter